How to turn AI into a COVidiot (part 2/3)

Here’s more proof that the AI was trained to answer illogically to support the narrative. Don’t miss the conclusions in part 3:

• Do COVID vaccines generate mucosal immunity?
It is not clear if COVID-19 vaccines generate mucosal immunity. Mucosal immunity refers to the immunity that is present in the mucous membranes that line the respiratory and gastrointestinal tracts. It is thought that this type of immunity may be important in protecting against respiratory viruses, such as COVID-19, which primarily infect the respiratory tract. Studies are ongoing to determine if COVID-19 vaccines generate mucosal immunity and to what extent.

However, the vaccines have been shown to generate strong antibody and T cell responses in the blood and studies have shown that the vaccines are highly effective in preventing severe disease, hospitalization and death, which are the primary goals of the vaccines.

Three Part Series:
How to turn AI into a COVidiot (Part 1) | (Part 2 | (Part 3)

• How could COVID vaccines generate mucosal immunity?
It is not clear exactly how COVID-19 vaccines might generate mucosal immunity, as this is an area of ongoing research. One possibility is that the vaccines may stimulate the production of antibodies and immune cells in the mucous membranes, similar to how they generate an immune response in the blood. Another possibility is that the vaccines may stimulate the production of immune cells that migrate to the mucous membranes and provide protection there.

It's also important to note that the COVID-19 vaccines currently authorized for emergency use by the FDA, Pfizer-BioNTech, Moderna and Johnson&Johnson, all use different platforms for their technology. Pfizer-BioNTech and Moderna vaccines use messenger RNA technology to instruct cells to produce a spike protein that is found on the surface of the virus. Johnson&Johnson vaccine uses an inactivated virus particle. These different technology platforms may have different effects on mucosal immunity.

It's important to note that the research on mucosal immunity is still ongoing and it's not clear yet how much this type of immunity will impact the overall effectiveness of the vaccines.

• Has it ever been shown how injected vaccines may stimulate the production of antibodies and immune cells in the mucous membranes?
It is not well understood how injected vaccines may stimulate the production of antibodies and immune cells in the mucous membranes. However, it is known that the immune system is capable of responding to antigens (such as viral proteins) in different parts of the body, including the mucous membranes. When a person is vaccinated, the immune system recognizes the antigens in the vaccine as foreign and generates an immune response, which includes the production of antibodies and immune cells that can recognize and respond to the antigen if it is encountered again in the future.

It's thought that the immune cells and antibodies generated in the blood after a vaccination may travel to the mucous membranes and provide protection there. But it's not yet clear how much this type of immunity will impact the overall effectiveness of the vaccines. Researchers are currently studying and trying to understand how the COVID-19 vaccines generate immunity in the mucous membranes, and if this type of immunity is important for protecting against respiratory viruses.

• Why was the nasal spray flu vaccine developed if injectable flu vaccines would have been effective in generating mucosal immunity?
The nasal spray flu vaccine, also known as the live attenuated influenza vaccine (LAIV), was developed as an alternative to the traditional injectable flu vaccine for several reasons. One reason is that the nasal spray vaccine can stimulate mucosal immunity, which is the immune response in the mucous membranes of the nose and throat. This can provide additional protection against the flu, as the flu virus often enters the body through the nose and throat. Additionally, the nasal spray vaccine is a live virus vaccine that replicates in the nose, which can result in a stronger immune response and potentially better protection against the flu.

• Injectable flu vaccines can't generate mucosal immunity?
Injectable flu vaccines can generate some level of mucosal immunity, but it is not as robust as the mucosal immunity generated by the nasal spray flu vaccine (LAIV) or other live attenuated vaccines. Injectable flu vaccines, also known as inactivated or killed flu vaccines, contain either killed or inactivated virus, which means that it can not replicate in the body. This can result in a weaker immune response, particularly in the mucous membranes of the nose and throat.

The nasal spray flu vaccine, on the other hand, is a live attenuated vaccine, which means that it contains a weakened form of the flu virus that can replicate in the body. This replication can stimulate a stronger immune response, including a stronger mucosal immunity.

• Can immune blood cells generate mucosal immunity?
Yes, immune blood cells can generate mucosal immunity. Mucosal immunity refers to the immune response that occurs in the mucosal tissues, such as the gut, respiratory tract, and genitourinary tract. Immune cells, including T cells and B cells, can migrate to these mucosal tissues and generate an immune response to protect the body against pathogens that enter through these mucosal surfaces. For example, T cells and B cells can produce antibodies that can neutralize pathogens, and T cells can also directly kill infected cells. This type of immunity is important for protecting the body against infections that enter through the mucosal surfaces.

Support Canada Free Press

• How do immune cells reach mucosal tissues?
Immune cells reach mucosal tissues through a process called homing. Homing is the ability of immune cells to migrate from the bloodstream to specific tissues in the body. This process is mediated by a variety of molecules, including cell adhesion molecules, chemokines, and integrins.

For example, when immune cells are activated in the lymphoid organs, such as the thymus and lymph nodes, they express specific cell adhesion molecules, such as integrins, on their surface. These molecules bind to complementary molecules, called addressins, that are present on the endothelial cells lining blood vessels in the mucosal tissues. This binding allows the immune cells to extravasate, or leave the bloodstream, and enter the mucosal tissues.

Once in the mucosal tissues, immune cells can migrate to specific locations using chemokines as guidance. Chemokines are signaling molecules that are produced by cells in the mucosal tissues and attract specific subsets of immune cells to the site of infection.

In summary, immune cells reach mucosal tissues by expressing specific cell adhesion molecules that bind to addressins on the blood vessel walls in the mucosal tissues, and by responding to chemokines that guide them to the site of infection.

• Having a viral respiratory infection, how long does it take for immune cells to reach mucosal tissues in the air tract?
The time it takes for immune cells to reach mucosal tissues in the respiratory tract after a viral infection can vary depending on a number of factors, including the virulence of the virus, the individual's age and overall health, and the individual's previous exposure to similar viruses. However, in general, it is thought that immune cells can begin to reach the respiratory mucosa within hours of infection.

Upon infection, the body will release chemical signals (such as cytokines) that will alert the immune system to the presence of a pathogen. This will then trigger the mobilization of immune cells from the bloodstream to the site of infection. For example, within hours of infection, circulating immune cells, like dendritic cells and macrophages, will migrate to the respiratory mucosa to engulf and present viral antigens to T cells to initiate the adaptive immune response.

Additionally, in the first days of infection, the virus may have already replicated and spread to the lymph nodes, where immune cells are activated and clonally expanded. These activated immune cells will then migrate to the site of infection to help clear the virus.

It is worth noting that the time it takes for the immune system to clear a viral infection can vary, and may take several days or even weeks. During this time, the body may experience symptoms of the infection, such as fever, cough, and difficulty breathing.

• Considering the time it takes to control a viral respiratory infection, having a prior flu vaccine, how would it reduce mucosal viral loads and transmission until the time it takes to clear the infection?
Having a prior flu vaccine may reduce the viral load and transmission of a viral respiratory infection, such as the flu, by providing some level of immunity to the virus. A vaccine works by exposing the immune system to a weakened or inactivated version of the virus, which allows the immune system to build up an immunity to it. If an individual is then exposed to the actual virus, their immune system is able to mount a more rapid and effective response, potentially reducing the severity of symptoms and the amount of virus present in the respiratory tract, which can help to reduce transmission to others. However, it is important to note that the flu vaccine may not provide complete protection against all strains of the flu, and that the effectiveness of the vaccine can vary depending on the match between the strains included in the vaccine and the strains circulating in the population.

VIEW Comments